What Alesse 28 Treats: Main Uses and Benefits

The core function of Alesse 28 serves as the primary therapeutic domain, which is to provide reliable support for pregnancy prevention in females of reproductive potential. In addition to this fundamental role, the medication is applied across domains where additional symptomatic support is needed.

This medication is commonly used to help with fertility management, offering effective support that helps ease the overall burden of unintended pregnancy. This primary use helps with fertility management and is considered relevant for easing disruptive cycle symptoms. The therapy is also commonly used to help with skin manifestations that create noticeable physiological strain, specifically for moderate acne in relevant patient groups.

Symptomatic Relief and Cycle Support

Beyond fertility management, the product is applied in settings where symptoms involving episodic or fluctuating manifestations are present, such as heavy menstrual flow, cycle irregularity, and pronounced painful cramping. This application supports general well-being and helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Supportive Management for Disruptive Menstrual Cycle Symptoms The therapy helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.

Regulatory References

1. Health Canada Product Monograph

Alesse 28 is officially indicated for use by post-menarchal females of reproductive potential for pregnancy prevention. Its use is also established for the treatment of moderate acne in certain female patients who elect to use an oral contraceptive.

Populations for Whom Use is Contraindicated

Use of this medicine is strictly contraindicated by regulatory agencies in several key populations, primarily those with elevated vascular risks. These absolute exclusions include women over 35 years of age who smoke and those with a history of or current thrombotic disorders (e.g., deep vein thrombosis, pulmonary embolism) or cerebrovascular disease. Contraindications also extend to females with known or suspected hormone-sensitive malignancies (like breast cancer), liver tumors, or severe active liver disease. Known or suspected pregnancy is an absolute contraindication, and the medicine is generally not recommended during breastfeeding.

Age-Related and Conditional Restrictions

The medicine is not indicated for use before menarche or in postmenopausal women. Use requires special consideration in certain conditions, such as immediately postpartum and before or after major surgery, due to temporary increases in thromboembolic risk. Females with uncontrolled high blood pressure or diabetes with vascular complications are also restricted from use.

Documented Drug–Drug Interactions

Alesse 28 (Ethinyl Estradiol/Levonorgestrel) is subject to officially documented interaction patterns categorized by their effect on drug concentrations and formal co-administration restrictions defined in regulatory prescribing information.

Contraindicated Combinations

Co-administration is formally prohibited with combination medicines used to treat Hepatitis C, specifically those containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This restriction is enforced due to the potential for significant elevation of liver enzymes. Oral Tranexamic Acid is also a contraindicated combination due to a documented pharmacodynamic synergism that increases the risk of thromboembolism.

Altered Hormone Exposure

The exposure to the active hormones is reduced when co-administered with strong CYP enzyme inducers, such as certain antiepileptic medicines (e.g., phenytoin, carbamazepine) and the herbal product St. John’s Wort. This reduction in plasma levels is officially documented as potentially compromising the drug's intended action. Conversely, Ethinyl Estradiol can inhibit the clearance of other medicines, leading to increased plasma levels of co-administered agents like Caffeine and Theophylline.

Administration Constraints

Mandatory separation rules exist for Hepatitis C regimens, requiring discontinuation of Alesse 28 for approximately two weeks before and after the regimen. Furthermore, incomplete absorption may occur if vomiting takes place within four hours of tablet intake.

Central Control: Suppression of Ovulation

This medication acts on the Hypothalamic-Pituitary-Ovarian (HPO) axis by providing synthetic hormone signals that act as agonists on target receptors. This mechanism suppresses the pulsatile release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) from the pituitary gland. This negative feedback mechanism prevents the hormonal signaling required for follicular growth and maturation, which results in the physiological consequence of anovulation.

---

Peripheral Modulation

The progestin component also exerts distinct peripheral actions. In the cervix, it promotes changes in glandular tissue that alter the consistency of the naturally occurring mucus, leading to a state of increased viscosity and reduced permeability. This physiological change results in increased resistance to the passage of reproductive cells into the upper reproductive tract. Additionally, the hormonal components act directly on the uterine lining (endometrium), causing a progestational transformation that results in an unstable and less developed uterine environment compared to a natural cycle, which contributes to the full spectrum of the observed mechanistic changes.

Alesse 28 administration follows a standardized, continuous 28-day regimen. The product is administered via the oral route as one tablet taken daily at the same time every day to maintain a consistent dosing interval. Each cycle requires strict adherence to the tablet sequence within the pack.

The regimen consists of taking one tablet for 28 consecutive days, which includes 21 active tablets containing a fixed dose of levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg, immediately followed by 7 inactive tablets (placebos). The inclusion of inactive tablets is a structural feature designed to maintain the patient's daily routine before starting the next course. The subsequent 28-day pack is initiated immediately after the last tablet of the previous pack, ensuring there is no tablet-free break between cycles.

There are specific procedural rules for beginning the medication. Treatment may be initiated using either the Day 1 Start (on the first day of the menstrual period) or the Sunday Start (on the first Sunday following the start of the menstrual period). A key procedural constraint is the requirement for a non-hormonal back-up method of contraception. A back-up method is used until the active tablets have been taken daily for seven consecutive days, particularly when the Sunday Start method is employed. The medication is indicated only for females of reproductive potential and is not intended for use before menarche or after menopause.

Research evidence / Overview of studies for Alesse 28

---

Evidence for use in Preventing Pregnancy (Contraception)

Research for this medication was evaluated for the prevention of pregnancy in healthy females of reproductive age. The research base relies on multicenter clinical trials where outcomes related to pregnancy incidence were monitored over defined time intervals. These trials typically research examined large groups of participants for periods of six cycles to one year. The primary metrics used to evaluate this indication were monitored in studies, including the annualized rate of pregnancy occurrence (often using the Pearl Index) and objective assessment of ovulation inhibition.

Clinical studies report measurements of the pregnancy rate observed under the specific conditions of the trials. The available data highlights a significant nuance: the research results apply only to the populations studied and largely assume consistent use. The evidence remains limited regarding the measured rates when patient adherence to the daily regimen is inconsistent.

Evidence for use in Treating Moderate Acne

Research was evaluated in studies for its use in individuals with moderate facial acne. The evidence for this area comes from high-quality study designs, primarily randomized, double-blind, placebo-controlled clinical trials (RCTs). These studies research examined healthy females, often adolescents and young adults, with conditions where symptoms may vary in intensity. The outcomes monitored included objective measurements such as the counting of inflammatory and non-inflammatory acne lesions, as well as scores based on clinician global assessments.

Research on Symptomatic Cycle Support

Studies exploring the class of combined oral contraceptives was evaluated in research for conditions characterized by fluctuating or episodic manifestations, such as heavy menstrual bleeding (HMB) and painful cramping (dysmenorrhea). The evidence for this area is largely derived from systematic reviews of the broader class of combined oral contraceptives (COCs) and comparative trials, rather than dedicated placebo-controlled studies for this specific formulation. The findings describe patterns observed in the studies where reported measurements evolved during the study period, including measurements of blood loss and symptom severity scores.

---

Key Research Gaps and Uncertainties

Long-term effects are not fully established regarding pregnancy outcomes and continuation of use beyond one year. For the acne indication, outcomes for severe acne are not fully established in the existing evidence. Finally, data for certain groups remain insufficient, particularly when applying trial results to women with a Body Mass Index (BMI) above 35 kg/m^2, and the research does not provide context but not individual predictions on how an individual in non-studied groups will respond.

Key Studies & References

1. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial

Common questions about Alesse 28 (FAQ)

---

Q: What is the difference between Alesse 28 and other birth control pills?

Official documentation describes Alesse 28 as a combined oral contraceptive (COC). This means it contains two types of synthetic hormones: a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). The product is defined by its specific low dosage of these two hormones.

Q: How long does it take for Alesse 28 to start working for contraception?

Regulatory guidance specifies that contraceptive reliability relies on taking an active tablet daily for seven consecutive days. Official instructions state that a non-hormonal back-up method of contraception should be used during this initial seven-day period.

Q: Can taking Alesse 28 affect future fertility?

Regulatory documents list temporary infertility after discontinuation of treatment as a potential adverse reaction reported in post-marketing surveillance. The return of the natural menstrual cycle is the physiological expectation upon cessation, though effects on long-term fertility are not directly addressed.

Q: Does Alesse 28 affect cholesterol levels?

Official safety information notes that combined oral contraceptives, as a class, may be associated with changes in carbohydrate and lipid effects. Lipids are fats in the blood, including cholesterol. These changes are generally recognized as a potential effect of combined hormonal contraceptives.

Q: Does Alesse 28 interact with antibiotics (as a general class)?

Regulatory documents state that certain medicines, including some antibiotics, may reduce the intended effectiveness of the pill by altering how the body processes the hormones. Official patient information may recommend the use of a back-up, non-hormonal method of contraception when using certain antibiotics concurrently.

Q: Is there a link between Alesse 28 and headaches or migraines?

Official documentation lists headaches as a very common adverse reaction and migraines as an uncommon adverse reaction. For individuals with a history of migraine with aura, regulatory documentation lists this as a condition that strictly prohibits or requires extreme caution for use.

Q: What happens when you stop taking Alesse 28?

Upon stopping the pill, a return to the user's natural menstrual cycle typically begins. Official documentation notes that temporary infertility after discontinuation of treatment has been reported as an adverse reaction. The return of the individual's natural menstrual cycle is the typical expected change.

Q: Can I start Alesse 28 if I am currently taking herbal supplements?

Regulatory documents specifically state that Herbal products containing St. John's Wort may reduce the effectiveness of the contraceptive hormones by inducing certain enzymes in the body. This interaction may result in breakthrough bleeding or reduced protection.

Q: Are there specific foods or drinks that interact with Alesse 28?

Official regulatory sources indicate that the consumption of grapefruit juice may lead to an increase in the blood levels of the hormone levonorgestrel. This change in blood concentration may be associated with an increased risk or severity of some side effects.

Q: Does Alesse 28 change appetite?

Official adverse reaction reports include both an increase in appetite and a decrease in appetite. Appetite changes are listed among the reported reactions associated with the use of the medicine.

Q: Is it possible to skip the placebo pills in Alesse 28?

The official instructions specify taking the 21 active pills followed by the 7 inactive pills. However, the official instructions outline specific protocols for certain situations, such as when active pills are missed in the third week, where the inactive pills may be omitted to avoid a hormone-free interval.

Q: What does the '28' in Alesse 28 refer to?

The number '28' in the name refers to the fact that the product is supplied in a 28-day cycle pack. This structured packaging includes 21 active hormone tablets and 7 inactive (placebo) tablets, designed to maintain a consistent daily routine.

Q: Is Alesse 28 considered a monophasic or multiphasic pill?

Official labeling describes the product as containing a fixed dose of ethinyl estradiol and levonorgestrel in all 21 active tablets. This fixed-dose composition is the defining characteristic of a monophasic oral contraceptive.

Q: Can Alesse 28 affect the results of laboratory tests?

Regulatory information indicates that the hormones in the contraceptive can affect the results of certain laboratory tests. These include tests for prothrombin time, coagulation factors, thyroid-binding globulin, and lipid profiles (blood fat levels).

Q: Does Alesse 28 cause changes in libido?

Official regulatory documentation lists change in libido (sex drive) as an adverse reaction that has been reported by patients receiving oral contraceptives.

Q: What happens if I take an extra active pill by mistake?

Regulatory overdosage information states that serious outcomes are not typically expected from taking an extra active pill. Symptoms commonly reported following the accidental ingestion of higher doses include nausea, vomiting, and a potential for withdrawal bleeding.

Q: Can Alesse 28 be taken while breastfeeding (general information)?

Official documents state that combined oral contraceptives should generally not be used during breastfeeding. This is because they may diminish the quantity and quality of breast milk, and small amounts of the hormones may pass into the breast milk.

Q: Can Alesse 28 interact with common over-the-counter pain relievers?

Regulatory information suggests that the estrogen component can interact with some common pain relievers, such as acetaminophen. This interaction may affect the clearance of the pain reliever, altering its intended effect.

Q: What should be done if I experience persistent nausea on Alesse 28?

Nausea is a very common side effect. Regulatory patient information describes the need to keep all appointments with a healthcare provider for the assessment of side effects and tolerance. Persistent reactions are typically managed through this established channel of healthcare follow-up.

Q: Are there common signs that Alesse 28 is not agreeing with someone?

Official documentation lists several common adverse reactions that users often report, such as headaches, nausea, irregular bleeding, and breast tenderness. These symptoms, along with any other concerns, are often reviewed with a healthcare provider to assess the product's tolerance.

Q: Is it normal to feel bloated after starting Alesse 28?

Official documents list gastrointestinal symptoms such as abdominal pain and bloating among the reported adverse reactions. Additionally, edema or fluid retention is also listed as an adverse reaction, which can sometimes be perceived as temporary bloating.

Q: Do you get your period on Alesse 28?

The bleeding that occurs during the use of the 7 inactive tablets is not a true menstrual period but is a predictable withdrawal bleed. This bleeding episode is caused by the temporary withdrawal of the active hormones.

Q: What are the inactive pills in Alesse 28 for?

The inactive pills (placebos) are included in the 28-day pack to maintain the patient's daily routine of pill-taking. This structural feature supports consistent adherence to the daily regimen and helps ensure the next pack is started on time.

Q: Does Alesse 28 help with acne?

Alesse 28 is officially indicated for the treatment of moderate acne in certain female patients who choose to use an oral contraceptive for birth control. Research studies support this use, showing a decrease in both inflammatory and total acne lesions.

Q: Is it possible to become pregnant while taking Alesse 28 correctly?

Official clinical trial data, which uses metrics like the Pearl Index to measure effectiveness, indicates that there is a low, non-zero annual probability of pregnancy even with consistent use.

Q: What happens if I miss a period while taking the active pills of Alesse 28?

Regulatory patient information states that if a user misses two consecutive expected bleeding episodes (withdrawal bleeds), the possibility of pregnancy must be formally considered. Official patient information requires that the possibility of pregnancy be formally considered before continuing with the next cycle.

Q: Is the effectiveness of Alesse 28 reduced by vomiting or diarrhea?

Official instructions specify that incomplete absorption may occur if vomiting takes place within four hours of tablet intake. Furthermore, regulatory patient information warns that severe or persistent diarrhea may also reduce the effectiveness of the pill.

Q: Can older adults use Alesse 28 (descriptive eligibility)?

Regulatory guidance strictly contraindicates use for women over 35 years of age who smoke. It is also not indicated for use in postmenopausal women. For non-smoking women over 35 who are not postmenopausal, the decision to use the product is subject to careful consideration of underlying health risks.

Q: Does Alesse 28 change the timing or flow of the menstrual cycle?

The pill is often associated with the establishment of a predictable withdrawal bleeding pattern during the inactive pill week. However, irregular or heavy uterine bleeding (spotting) is also reported as a very common side effect, particularly during the first few cycles of use.

Q: Are there general warnings about travel and taking Alesse 28?

While there is no specific 'travel warning,' the official regulatory instructions emphasize that the tablet must be taken daily at the same time every day to maintain a consistent dosing interval. This implies a need for planning when crossing time zones to ensure the consistent dosing interval is maintained.

Q: What are the typical ingredients found in the placebo pills of Alesse 28?

The placebo tablets are officially described as inert or inactive and contain no hormones. Their composition primarily consists of excipients (inactive ingredients) such as lactose, cellulose, and magnesium stearate, and may include a colorant.

Storage Requirements

Alesse 28 (levonorgestrel and ethinyl estradiol tablets) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and kept away from excess moisture and heat to maintain stability. The official labeling explicitly states that the medication should be kept from freezing.

For general handling, the tablets must remain in their original container and be kept tightly closed. Safety regulations mandate that the product be stored out of the reach of children and pets in a secure location.

Disposal Instructions

Official disposal guidance instructs users not to keep outdated or unneeded medicine. Specific to the regimen, if a user misses a certain number of active tablets in a row in Week 3, the patient instructions require them to safely dispose of the rest of the pill pack. Unused medicine should be disposed of in accordance with local drug take-back programs or by consulting a healthcare professional for proper guidance.